ACA
CARM

Avoro Capital Advisors’s Carisma Therapeutics CARM Stock Holding History

Avoro Capital Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-340,000
Closed -$14.6M – 38
2018
Q3 		$14.6M Hold
340,000
– – 0.67% 26
2018
Q2 		$13.3M Buy
+340,000
New +$15M 0.51% 31

Other funds holding CARM

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Avoro Capital Advisors's CARM Position: Q4 2018 in Review

Avoro Capital Advisors sold out of Carisma Therapeutics (CARM) in Q4 2018, closing a stake of 340,000 shares — an estimated $14.6M sold.

Avoro Capital Advisors first reported a position in CARM in Q2 2018 and held it in 2 quarters. The position peaked at $14.6M in Q3 2018. 48 funds tracked by Wall St. Rank hold CARM as of Q4 2018.

  • Avoro Capital Advisors reported no remaining Carisma Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Avoro Capital Advisors sold 340,000 Carisma Therapeutics shares in Q4 2018, an estimated $14.6M.
  • Avoro Capital Advisors first reported a position in Carisma Therapeutics in Q2 2018 and held it in 2 quarters.
  • Avoro Capital Advisors's Carisma Therapeutics position peaked at $14.6M in Q3 2018.
  • 48 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2018.

Based on Avoro Capital Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.